Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Rilparencel (REACT®) in Chronic kidney disease, Type 2 diabetes. The expected timing is based on the latest available company guidance and may change.
08/10/26:- PROACT 1 efficacy enrollment completed. Full enrollment expected H2 2026. eGFR data expected Q2 2027. Confirmatory data expected H2 2029.
Verification
Confirm timing and program details against the company announcement or filing.